Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director Sells $217,000.00 in Stock
by Kim Johansen · The Markets DailyProtagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) Director William D. Waddill sold 4,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $54.25, for a total transaction of $217,000.00. Following the transaction, the director now owns 13,130 shares in the company, valued at $712,302.50. The trade was a 23.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Protagonist Therapeutics Stock Performance
Shares of Protagonist Therapeutics stock traded down $0.17 during midday trading on Wednesday, reaching $54.35. 1,043,472 shares of the company’s stock traded hands, compared to its average volume of 740,072. The stock has a 50 day moving average of $40.25 and a 200-day moving average of $42.39. Protagonist Therapeutics, Inc. has a 12 month low of $24.22 and a 12 month high of $60.60. The company has a market cap of $3.34 billion, a PE ratio of 20.43 and a beta of 2.34.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its quarterly earnings data on Friday, February 21st. The company reported $1.98 EPS for the quarter, topping the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The business had revenue of $170.64 million during the quarter, compared to analyst estimates of $56.65 million. On average, equities analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on PTGX shares. JPMorgan Chase & Co. upped their price objective on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. JMP Securities reaffirmed a “market outperform” rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Wedbush reissued an “outperform” rating and issued a $70.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, March 11th. The Goldman Sachs Group dropped their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, February 24th. Finally, Truist Financial lifted their price target on Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a “buy” rating in a research note on Tuesday, March 11th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.56.
Check Out Our Latest Research Report on PTGX
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in PTGX. Bank of Montreal Can grew its stake in Protagonist Therapeutics by 4.5% in the fourth quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock worth $241,000 after purchasing an additional 270 shares during the period. Maryland State Retirement & Pension System grew its holdings in Protagonist Therapeutics by 1.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock worth $779,000 after purchasing an additional 278 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Protagonist Therapeutics by 10.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock valued at $121,000 after purchasing an additional 295 shares in the last quarter. Louisiana State Employees Retirement System lifted its holdings in shares of Protagonist Therapeutics by 1.1% during the fourth quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock valued at $1,112,000 after purchasing an additional 300 shares during the last quarter. Finally, KBC Group NV boosted its position in shares of Protagonist Therapeutics by 54.4% in the 4th quarter. KBC Group NV now owns 2,093 shares of the company’s stock worth $81,000 after purchasing an additional 737 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Featured Articles
- Five stocks we like better than Protagonist Therapeutics
- 3 Healthcare Dividend Stocks to Buy
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- What Are Earnings Reports?
- Alphabet’s Officially In A Bear Market—Time To Buy?
- What is the MACD Indicator and How to Use it in Your Trading
- D-Wave and Quantum Supremacy: Implications For Investors